224 filings
Page 8 of 12
8-K
ex2u1s fw045ghgns
6 Apr 18
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder
12:00am
8-K
e8lomyk
20 Mar 18
VistaGen Therapeutics Receives a Notice of Allowance for Another Key
12:00am
8-K
2h8zssbplsyp9cuhjkk
8 Mar 18
VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101
12:00am
8-K
orx y8y7r27wa27x4
13 Feb 18
VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results
12:00am
8-K
npu o0zn3j3u
30 Jan 18
VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder
12:00am
8-K
33bw ifdws0
8 Jan 18
VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder
12:00am
8-K
shj2ms4l
13 Dec 17
VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
12:00am
8-K
c9azd881yc72ueh
8 Dec 17
VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent
12:00am
8-K
aul3ce1ho24u21
6 Dec 17
VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101
12:00am
8-K
qywxb
9 Nov 17
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update
12:00am
8-K
7dpfejy
7 Nov 17
VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression
12:00am
8-K
64wg4 f5tt6aqm3c
26 Oct 17
VistaGen Announces FDA Authorization to Initiate Phase 2 Study
12:00am
8-K
058ynpaydg8f9e
2 Oct 17
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101
12:00am
8-K
wj63h riv06
20 Sep 17
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
0eqxk2c
31 Aug 17
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
12:00am
8-K
o69kof
14 Aug 17
VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update
12:00am
8-K
i3ucvj
9 Aug 17
Other Events
12:00am
8-K
829x5nb7bt
29 Jun 17
VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update
12:00am
8-K
0317uhc qy
1 May 17
VistaGen Therapeutics’ Largest Stockholder Signs
12:00am
8-K
ejo1obr9jor30n
28 Apr 17
Other Events
12:00am